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Abstract
Liver cancer will continue to be a major disease threatening the lives and health 
of our people in the next few decades. In recent years, with the development of 
early diagnosis and treatment of liver cancer, precise liver resection, and the 
development of targeted and immunotherapeutic drugs, the survival rate of liver 
cancer patients has been improved. Nevertheless, due to the high heterogeneity 
of liver cancer, patients with liver cancer in the same clinical stage still have great 
differences in response to treatment and prognosis. New staging and classification 
indicators are urgently needed to facilitate accurate diagnosis and treatment of 
liver cancer, so as to further improve the survival rate of patients. The continu-
ous progress and development of multi-omics technology, single-cell technology, 
tumor molecular visualization technology and medical artificial intelligence, etc., 
make the molecular classification of liver cancer more and more approaching the 
true nature of tumor biological characteristics, thus contributing to the accurate 
diagnosis and treatment of liver cancer.
Keywords: hepatocellular carcinoma, tumor heterogeneity, molecular typing, 
diagnosis, treatment
1. Introduction
Liver cancer is a major disease that seriously threatens the lives and health of 
our people. In recent years, the clinical diagnosis and treatment of liver cancer and 
innovative research have made remarkable progress. Nevertheless, due to the high 
heterogeneity of liver cancer, patients with liver cancer of the same clinical stage still 
have great differences in response to treatment and prognosis. There is an urgent 
need for new staging and classification indicators to facilitate accurate diagnosis and 
treatment of liver cancer, so as to further improve the survival rate of patients.
Liver cancer is considered to be one of the most heterogeneous tumors [1]. Due 
to the high heterogeneity of liver cancer, no “cancer-dependent genes” related to 
liver cancer have been found so far, which makes the therapeutic effect of molecu-
lar targeted therapy of liver cancer very small and lacks theoretical basis [2]. The 
heterogeneity of liver cancer includes inter-tumor heterogeneity and intra-tumor 
heterogeneity, both of which are distinguished from each other and closely related. 
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Among them, there are both genetic heterogeneity and microenvironment hetero-
geneity. Tumor heterogeneity indicates the insufficiency of “genetic characteristics 
and microenvironmental information obtained from a single biopsy”, which has 
important theoretical value and clinical significance for studying the develop-
ment history of individual liver cancer, overcoming drug resistance, and achieving 
individual precise treatment. The continuous progress and development of multi-
omics technology, single-cell technology, tumor molecular visualization technology, 
and medical artificial intelligence have brought the molecular classification of liver 
cancer closer to the true nature of tumor biological characteristics, thereby helping 
the implementation and health of accurate diagnosis and treatment of liver cancer 
China’s strategic planning.
2. Molecular typing based on transcriptome
With the progress of gene chips and second-generation sequencing technology, 
it is possible to analyze tumor gene expression changes without bias at the whole 
genome level, and the molecular typing of liver cancer first started from the explo-
ration of transcriptomics. The gene microarray analysis of primary and metastatic 
HCC showed that the gene expression signature of primary HCCs with accompany-
ing metastasis was very similar to that of their corresponding metastases, implying 
that genes favoring metastasis progression were initiated in the primary tumors. 
The constructed 153 gene expression markers could divide HCC into metastatic and 
non-metastatic types with a prediction accuracy of 78% [3]. At present, a number 
of studies have divided liver cancer into proliferative and non-proliferative types 
through transcriptomics methods, with the two molecular types each accounting 
for 50% [4–10]. The proliferative type is characterized by activation of PI3K-Akt–
mTOR, Ras-MAPK, MET, and other cell proliferation-related signaling pathways, 
which are usually associated with HBV infection, and are driven by TP53 inactiva-
tion, FGF19, and/or CCND1 amplification, and has a poor prognosis. The non-
proliferative type is more heterogeneous and is usually associated with alcoholic 
liver disease and HCV infection, with a relatively good prognosis. The proliferative 
type can be further divided into Hoshida S1 and S2 subtypes [4]. Strong enrichment 
of the WNT signature in subclass S1 compared with S2 or S3, suggesting prefer-
ential WNT activation in S1 tumors. Hoshida S2 tumors were strongly enriched in 
signatures of EpCAM、AFP and IGF2 positivity. The non-proliferative Hoshida 
S3 subtype is still heterogeneous, including the classical Wnt pathway activation 
subtype mediated by CTNNB1 mutation [5]. The Cancer Genome Atlas (TCGA) 
analyzed 363 hepatocellular carcinoma cases by whole-exome sequencing and DNA 
copy number analyses, DNA methylation, RNA, miRNA, and proteomic expression 
also. Integrative molecular HCC subtyping incorporating unsupervised clustering 
of five data platforms identified three subtypes:iClust1 ~ 3. Then iClust1 consisted 
predominantly of Hoshida S2 patients whereas iClust 2 subtype corresponds to 
Hoshida S3 subtype (CTNNB1 mutant subtype), and iClust 3 subtype corresponds 
to TP53 mutation and Hoshida S1 subtype [7]. These transcriptome-based molecu-
lar typing revealed the intrinsic molecular characteristics of liver cancer and had 
potential clinical significance.
3. Molecular typing based on tumor microenvironment
The immunoinflammatory microenvironment is the seventh characteristic 
of tumors [11]. Hepatocellular carcinoma is a typical immunoinflammatory and 
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microenvironment-related tumor. Imbalance of immune-inflammatory response 
in the microenvironment is one of the key mechanisms for the occurrence and 
development of liver cancer [12, 13]. It has been discovered that the prognosis 
model of HCC constructed by integrating microenvironmental immune response, 
angiogenesis, and interstitial reaction can accurately predict the recurrence and 
metastasis of patients after surgery, highlighting the importance of stromal biology 
in HCC progression [14]. Based on immune-related gene expression level in the 
tumor microenvironment, HCC can be divided into the type of immune activation, 
the depletion of immune and immune exemption, various accounts for 10% ~ 25%, 
including immune activation type high expression of adaptive immune-related 
genes, immune depletion type high expression of TGF-β mediated immune sup-
pression and T cell depletion related genes, immune exemption type is character-
ized by lack of T cells and CTNNB1 mutations [8]. According to the situation of 
immune cell infiltration, it can be divided into three subtypes: Immune-high, 
Immune-mid, and Immune-low. The Immune-high subtype was characterized by 
increased B−/plasma-cell and T cell infiltration, and the Immune-high subtype and 
B-cell infiltration were identified as independent positive prognostic factors. Low 
immune subtypes with a high Treg/CD4 ratio had the worst prognosis [15]. Further 
research found that: Comprehensive liver cancer immune microenvironment score 
(CD3, CD27, CD68, CD103, PD1) and tumor size, degree of differentiation, the 
prognosis model constructed by GGT is significantly better than the traditional 
clinical staging, and patients can be divided into high, medium, and Low-risk 3 
groups [16]. Immune microenvironment typing has a certain clinical guiding value. 
For example, patients with Immune exemption type characterized by CTNNB1 
mutations do not respond to programmed death-receptor-1(PD-1) / programmed 
death-ligand 1(PD-L1) inhibitors due to the lack of T cell infiltration. In addition, 
β-catenin activation conferred resistance to anti–PD-1 therapy in murine models 
[17]. There is no doubt that microenvironmental immune cells are highly plastic and 
heterogeneous. The results of single-cell sequencing showed that there were 11 T 
cell subsets with different functional phenotypes in the HCC microenvironment. 
It is necessary to further elucidate the microenvironmental characteristics and 
regulatory mechanisms of each subtype [18]. In addition, the liver itself is the most 
common metastatic organ for liver cancer, and the interaction between liver cells 
and immune cells creates a “metastasis-promoting microenvironment.” The results 
of a number of studies have shown that the microenvironment of the adjacent liver 
tissue or tumor junction area plays an important role in the invasion and metastasis 
of liver cancer [19, 20]. Studies have shown that 17 inflammatory cytokine gene 
expression markers such as CSF1 can divide the adjacent tissues into metastasis-
promoting microenvironment type and anti-metastatic microenvironment type, 
among which metastasis-promoting microenvironment type has high expression of 
Th2 cytokines and low expression of Th1 Cytokine as a feature [21]. Hoshida et al. 
[22]. analyzed the expression profile of adjacent tissues of liver cancer and found 
that gene expression markers composed of 186 genes related to liver function and 
inflammation can divide liver cancer into good prognosis and poor prognosis. The 
poor prognosis is characterized by late recurrence, suggesting that the gene markers 
in the adjacent tissues may be related to the new liver cancer.
The presence of multifocal tumors, developed either from intrahepatic metasta-
sis (IM) or multicentric occurrence (MO), is a distinct feature of hepatocellular car-
cinoma (HCC). The results of the study show that there are significant differences 
between IM and MO tumors, and their immune microenvironment also shows 
temporal and spatial heterogeneity: IM has fewer T lymphocytes and abundant M2 
macrophage infiltration, while MO has higher Suppressive immune checkpoints, 
which also resulted in immune editing mainly occurring in MO rather than IM. 
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Similar to the mutation profile, the neoantigens and TCR components shared in 
tumors are higher in IM patients, but very few in MO. In addition, the loss of HLA 
heterozygosity occurs in 17% of multifocal liver cancers, which prevents a large 
number of predicted neoantigens from being effectively presented to the immune 
system and reduces the actual mutation load, especially in IM patients [23].
Immune inflammatory cells in the tumor microenvironment are not only an 
important prognostic factor but also determine their response to specific treatment 
methods, especially tumor immunotherapy. With the advancement of flow cytom-
etry, immunostaining, and biological information technology, we can identify 
and classify the microenvironmental immune cell population with unprecedented 
precision. Immune inflammatory cells in the liver cancer microenvironment have 
significant inter-tumor heterogeneity and intra-tumor tissue heterogeneity in 
terms of density, location distribution, phenotype, and functional status; while the 
migration and differentiation of immune cells in tissues have temporal and spatial 
differences Qualitatively, liver cancer cells use this characteristic of immune cells 
to dynamically domesticate and edit them, leading to local immunosuppression, 
suggesting the plasticity of the liver cancer microenvironment [24–26].
4. Molecular typing based on proteome
Proteins are the direct executors of life activities and proteomics is one of the 
effective methods to search for molecular markers. The molecular characteristics 
of 110 cases of early hepatocellular carcinoma were analyzed and compared 
by proteomics [27]. The heterogeneity of early hepatocellular carcinoma was 
divided into the subtypes S-I, S-II, and S-III, each of which has a different clini-
cal outcome. TGF-β and other tumor proliferation-related proteins were highly 
expressed in the S-III subtype, which was consistent with the Hoshida S1 subtype, 
and the prognosis was poor. S-II and S-I subtypes were characterized by high 
expression of Wnt and CTNNB1, consistent with Hoshida S2 and S3 subtypes. 
Proteomics is also an effective way to find drug targets. At present, the direct 
targets of liver cancer-targeted drugs with multi-kinase inhibitors and immu-
notherapy with immune checkpoint inhibitors are all proteins. S-III, which is 
characterized by disrupted cholesterol homeostasis, is associated with the lowest 
overall rate of survival and the greatest risk of a poor prognosis after first-line 
surgery. The knockdown of sterol O-acyltransferase 1 (SOAT1)-high expression of 
which is a signature specific to the S-III subtype-alters the distribution of cellular 
cholesterol, and effectively suppresses the proliferation and migration of hepa-
tocellular carcinoma. Finally, on the basis of a patient-derived tumor xenograft 
mouse model of hepatocellular carcinoma, that treatment with avasimibe, an 
inhibitor of SOAT1, markedly reduced the size of tumors that had high levels of 
SOAT1 expression, which indicates that SOATI may become a new target of S-III 
subtype, namely Hoshida S1 subtype liver cancer [27]. Gene mutation induced 
by aristolochic acid is a characteristic pathogenic factor in China and even in Asia 
except for viral hepatitis B [28]. The mutation “fingerprint” of aristolochic acid is 
significantly positively correlated with tumor mutation burden, tumor neoanti-
gen burden, CD8+ T cell infiltration, and immune microenvironment tolerance, 
suggesting these patients may benefit from immunotherapy [18]. On the other 
hand, the microenvironment of CTNNB1 mutation patients is immuno-privileged 
and may not benefit from immunotherapy. Further multi-omics analysis of liver 
cancer found that CTNNB1 mutation is related to the phosphorylation of serine 
36 in ALDOA (fructose-1,6-bisphosphate aldolase) [29].ALDOA phosphorylation 
promotes tumor cell proliferation by promoting anaerobic glycolysis and knocking 
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down ALDOA significantly inhibits tumor proliferation. Therefore, ALDOA may 
be an important potential therapeutic target for CTNNB1 mutant liver cancer.
5. Molecular typing based on metabolic characteristics
Cell metabolism is downstream of gene regulation and protein action net-
work, reflecting the terminal information of life activities. The liver is the largest 
metabolic organ of the human body, and metabolic reprogramming undoubtedly 
plays an important role in the occurrence and development of liver cancer [30]. 
Multi-omics research results show that glycolysis and fatty acid metabolism are 
up-regulated in liver cancer tissues, while liver-specific metabolic pathways are 
down-regulated in liver cancer tissues, such as gluconeogenesis, detoxification, 
bile acid metabolism, and urea-ammonia metabolism [23]. The combined mark-
ers of glycine cholic acid and phenylpropionate tryptophan identified based on 
metabonomics technology can accurately diagnose liver cancer 1 year in advance 
[31]. The high heterogeneity of the liver cancer mutation spectrum and expres-
sion spectrum will inevitably lead to the heterogeneity of its metabolome level. By 
constructing a genome-scale metabolic network model, liver cancer can be divided 
into iHCC type 1 to 3. iHCC1 showed the highest fluxes in the metabolism of amino 
acids, cofactors and coenzymes, pyruvate, fatty acid oxidation, carnitine shuttle, 
steroids, TCA, and oxidative phosphorylation. iHCC2 exhibited specific features 
including lower fatty acid biosynthesis and high glutamine metabolism, and 
β-catenin–associated up-regulated fatty acid oxidation. Finally, iHCC3 tumors were 
associated with multiple features of malignant tumors, including hypoxic behavior, 
epithelial-to-mesenchymal transition, higher fluxes in fatty acid biosynthesis, and 
a strong Warburg effect [32]. Whether tumor metabolic reprogramming is the 
initiating factor of cancer or the accompanying result of cancer, there is still much 
controversy. Preliminary research results show that amino acid metabolism-related 
genes such as proline synthase PYCR1 play an important role in the occurrence and 
development of liver cancer [33].
6. Conclusion
In recent years, many breakthroughs have been made in the treatment of liver 
cancer. Following sorafenib, lenvatinib, regorafenib, cabozantinib and combina-
tion therapies centered on immune checkpoints have come out to promote the 
progress of liver cancer drug treatment. However, due to the high heterogeneity of 
liver cancer, the overall effectiveness of the above drugs is still limited. Accurate 
molecular classification of liver cancer not only contributes to the decision-making 
of individualized diagnosis and treatment of liver cancer, and personalized drug 
treatment, but also greatly deepens clinicians’ understanding of the complexity 
and heterogeneity of liver cancer, so as to formulate a more accurate and effective 
treatment strategy. The new molecular typing system should be closely integrated 
with clinical-pathological information, which can not only reflect changes at 
the molecular level but also have guiding significance for clinical diagnosis and 
personalized treatment or predicting prognosis. The author believes that with 
the progress and development of multi-omics technology, single-cell technology, 
tumor molecular visualization technology, and medical artificial intelligence, the 
molecular classification of liver cancer will become closer and closer to the essence 
of tumor biological characteristics, and ultimately achieve disease precision 
treatment.
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